In Vivo Modeling of the Morbid Human Genome using Danio rerio
- Authors
- Niederriter, A.R., Davis, E.E., Golzio, C., Oh, E.C., Tsai, I.C., and Katsanis, N.
- ID
- ZDB-PUB-130905-20
- Date
- 2013
- Source
- Journal of visualized experiments : JoVE (78): e50338 (Journal)
- Registered Authors
- Davis, Erica, Katsanis, Nicholas, Tsai, I-Chun
- Keywords
- none
- MeSH Terms
-
- Animals
- Disease/genetics*
- Genome, Human*
- Genomics/methods*
- Humans
- Microinjections
- Models, Animal*
- Morpholinos/administration & dosage
- Morpholinos/genetics
- Oligonucleotides, Antisense/administration & dosage
- Oligonucleotides, Antisense/genetics
- RNA, Messenger/administration & dosage
- RNA, Messenger/genetics
- Zebrafish/genetics*
- PubMed
- 23995499 Full text @ J. Vis. Exp.
Here, we present methods for the development of assays to query potentially clinically significant nonsynonymous changes using in vivo complementation in zebrafish. Zebrafish (Danio rerio) are a useful animal system due to their experimental tractability; embryos are transparent to enable facile viewing, undergo rapid development ex vivo, and can be genetically manipulated. These aspects have allowed for significant advances in the analysis of embryogenesis, molecular processes, and morphogenetic signaling. Taken together, the advantages of this vertebrate model make zebrafish highly amenable to modeling the developmental defects in pediatric disease, and in some cases, adult-onset disorders. Because the zebrafish genome is highly conserved with that of humans (~70% orthologous), it is possible to recapitulate human disease states in zebrafish. This is accomplished either through the injection of mutant human mRNA to induce dominant negative or gain of function alleles, or utilization of morpholino (MO) antisense oligonucleotides to suppress genes to mimic loss of function variants. Through complementation of MO-induced phenotypes with capped human mRNA, our approach enables the interpretation of the deleterious effect of mutations on human protein sequence based on the ability of mutant mRNA to rescue a measurable, physiologically relevant phenotype. Modeling of the human disease alleles occurs through microinjection of zebrafish embryos with MO and/or human mRNA at the 1-4 cell stage, and phenotyping up to seven days post fertilization (dpf). This general strategy can be extended to a wide range of disease phenotypes, as demonstrated in the following protocol. We present our established models for morphogenetic signaling, craniofacial, cardiac, vascular integrity, renal function, and skeletal muscle disorder phenotypes, as well as others.